<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752280</url>
  </required_header>
  <id_info>
    <org_study_id>GRIPS</org_study_id>
    <nct_id>NCT04752280</nct_id>
  </id_info>
  <brief_title>Glioblastoma Radiotherapy Using IMRT or Proton Beams</brief_title>
  <acronym>GRIPS</acronym>
  <official_title>Glioblastoma Radiotherapy Using IMRT or Proton Beams</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation therapy is an integral part of the multimodal primary therapy of glioblastomas. As&#xD;
      the overall prognosis in this tumor entity remains unfavorable, current research is focused&#xD;
      on additional drug therapies, which are often accompanied by increases in toxicity. By using&#xD;
      proton beams instead of photon beams, it is possible to protect large parts of the brain&#xD;
      which are not affected by the tumor more effectively. An initial retrospective matched-pair&#xD;
      analysis showed that this theoretical physical benefit is also clinically associated with a&#xD;
      reduction in toxicity during therapy and in the first few months thereafter. The aim of the&#xD;
      GRIPS study is to prospectively test this clinical benefit in a randomized, open-label Phase&#xD;
      III study. Patients are treated in the study using either modern photon radiation techniques&#xD;
      (standard arm) or proton beams (experimental arm). The primary endpoint is the cumulative&#xD;
      toxicity CTC grade 2 and higher in the first 4 months. Secondary endpoints include overall&#xD;
      survival, progression-free survival, quality of life, and neurocognition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">October 19, 2027</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative rate of toxicity</measure>
    <time_frame>from start of radiotherapy until progress (max. month 4)</time_frame>
    <description>Cumulative rate of toxicity ≥ grade 2 (until progress (max. month 4))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>start of therapy until 6 weeks after end of therapy (end of therapy up to month 4)</time_frame>
    <description>according to CTC AE V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>6 weeks after end of therapy (end of therapy up to month 4)</time_frame>
    <description>according to CTC AE V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life according to EORTC QLQ-C30</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>according to EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life according to EORTC QLQ-BN20</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>according to EORTC QLQ-BN20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognition</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>according to Hopkins Verbal Learning Test-Revised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring number of Lymphocytes count</measure>
    <time_frame>end of therapy up to month 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Proton irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irradiation applied with protons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Photon IMRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Photon irradiation applied as intensity-modulated radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton irradiation</intervention_name>
    <description>proton irradiation applied as follows: 30 x 2 Gy(RBE) 33 x 1,8 Gy (RBE), or 15 x 2,67 Gy (RBE)</description>
    <arm_group_label>Arm A: Proton irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photon irradiation</intervention_name>
    <description>proton irradiation applied as follows: 30 x 2 Gy 33 x 1,8 Gy, or 15 x 2,67 Gy</description>
    <arm_group_label>Arm B: Photon IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed gliomblastoma WHO IV (operated or after biopsy)&#xD;
&#xD;
          -  Indication for radiotherapy / radiochemotherapy&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  KI ≥ 60% or ECOG 0/1&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Sufficient effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is not able to consent&#xD;
&#xD;
          -  Previous radiotherapy in the brain or skull base&#xD;
&#xD;
          -  Active medical implants for which there is no ion radiation authorization at the time&#xD;
             of treatment (e.g., cardiac pacemaker, defibrillator, ...)&#xD;
&#xD;
          -  Contraindication to MRI imaging&#xD;
&#xD;
          -  Simultaneous participation in another clinical trial that could influence the outcome&#xD;
             of this study or other study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Klaus Herfarth, Prof. Dr.</last_name>
    <phone>+49 6221 56 34093</phone>
    <email>studienkoordination.RAD@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Herfarth, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rita Engenhart-Cabillic, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Münter, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Prof. Dr. Dr. Jürgen Debus</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

